Technology | Vascular Closure Devices | December 14, 2017

Vasorum Launches Celt ACD Second-Generation Vascular Closure Device in the U.S.

First commercial cases demonstrated excellent time to hemostasis in a variety of clinical situations

Vasorum Launches Celt ACD Second-Generation Vascular Closure Device in the U.S.

December 14, 2017 — Vasorum Ltd, the developer and manufacturer of the novel Celt ACD vascular closure device, has added a 7F-sized Celt ACD device to its range following U.S. Food and Drug Administration (FDA) approval of its premarket approval (PMA) supplement. Celt ACD is indicated for arterial puncture closure in both diagnostic and interventional cardiology and radiology patients. Vasorum said the device offers excellent time to hemostasis in a wide variety of clinical situations. The second-generation Celt ACD devices now available in both the United States and Europe have a new improved delivery system which has been designed to enhance the user experience during deployment.

The first commercial cases in the U.S. have been carried out by Shing-Chiu Wong, M.D., professor of medicine at Weill Cornell Medicine in New York. Based on his use, Wong commented that the "Celt ACD range of closure devices are addressing the clear need for quicker and more efficient methods of increasing patient throughput in healthcare facilities, and they provide doctors and patients with a solution which can efficiently manage arterial closure following vascular procedures."

Clinical cases have also been carried out by Richard Kovach, M.D., division director, interventional cardiology and medical director, cardiac catheterization laboratory at Deborah Heart and Lung, Browns Mills, N.J. Kovach commented that he "was impressed with the performance of Celt ACD in patients with severe arterial disease undergoing complex interventional procedures." Additionally, he believes that "Celt ACD has the potential to become the workhorse closure device in cath labs."

There are currently over 8 million catheter procedures performed annually, which support an estimated $1 billion femoral artery closure device market. The number of procedures is expected to exceed 10 million by 2020. In addition to interventional cardiology procedures, the market growth is being driven by an increasing number of peripheral vascular, neuro-vascular and other catheter procedures which demand more patient-friendly devices and more efficient patient discharge from hospitals.         

For more information:

Related Content

SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.,

Major mergers in interventional cardiology.

Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Videos | Cath Lab | May 07, 2018
Imran Ahmad, M.D., medical director of interventional cardiology, explains some of the new technologies his labs have
360 Photos | Cath Lab | April 20, 2018
A 360 degree view of the newest cath lab at Northwestern Medicine Central DuPage Hospital in Winfield, Ill., located
SCAI Announces Global Lecture Series for 2018 Scientific Sessions
News | Cath Lab | April 18, 2018
Many of the world’s leading interventional cardiologists and cardiovascular professionals will convene in San Diego,...
Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.

Figure 1. Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.


Figure 2. Serial optical coherence tomography findings of the representative case treated with shockwave intravascular lithotripsy.

Feature | Cath Lab | April 16, 2018 | Azeem Latib, M.D.
Over the last decade, there have been considerable developments in procedural techniques and technology facilitating
Videos | Cath Lab | March 27, 2018
Roxana Mehran, M.D., FACC, FACP, FCCP, FESC, FAHA, FSCAI, professor of medicine and director of interventional cardio
American College of Cardiology Expands Patient Navigator Program
News | Cath Lab | March 21, 2018
March 21, 2018 — Hundreds of hospitals across the United States will have access to tools and resources to help impro
Overlay Init